Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Shukui Qin(Nanjing University of Chinese Medicine), Li Qiu(Sichuan University), Shanzhi Gu(Hunan Cancer Hospital), Xiaoming Chen(Guangdong Provincial People's Hospital), Li-zhu Lin(Guangzhou University), Zishu Wang(First Affiliated Hospital of Bengbu Medical College), Aibing Xu(Nantong Tumor Hospital), Xi Chen(Guangdong Provincial People's Hospital), Cuncai Zhou(Jiangxi Provincial Cancer Hospital), Zhenggang Ren(Fudan University), Lin Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Li Xu(Sun Yat-sen University), Yuxian Bai(Harbin Medical University), Lei Chen(Shantou University), Jun Li(First Affiliated Hospital of Guangzhou Medical University), Hongming Pan(Sir Run Run Shaw Hospital), Bangwei Cao(Capital Medical University), Weijia Fang(First Affiliated Hospital Zhejiang University), Wei Wu(The Sixth People's Hospital of Shenyang), Ge Wang(Army Medical University), Ying Cheng(Jilin Province Tumor Hospital), Zhuang Yu(Qingdao University), Xu Zhu(Peking University), Da Jiang(Hebei Medical University), Yinying Lu(Chinese PLA General Hospital), Huaming Wang(Chinese PLA General Hospital), Jianming Xu(Chinese PLA General Hospital), Li Bai(Chinese PLA General Hospital), Yunpeng Liu(First Hospital of China Medical University), Hailan Lin(Fujian Provincial Cancer Hospital), Changping Wu(The First People's Hospital of Changzhou), Yang Zhang(Dalian Medical University), Ping Yan(Jiangsu Hengrui Medicine (China)), Chunlei Jin(Jiangsu Hengrui Medicine (China)), Jianjun Zou(Jiangsu Hengrui Medicine (China))
Cited by 251
Abstract
Related Papers
No related papers found
Powered by citation graph analysis